| Field | Specification |
|---|---|
| Target | |
| Alternative names | Hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS domain-containing protein 8; HIF1A; MOP1; PASD8 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human HIF-1 alpha |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 17H18 is a rabbit monoclonal antibody that recognizes hypoxia-inducible factor 1-alpha (gene HIF1A) in human samples and is validated for Western blot, IHC, ICC/IF, immunoprecipitation and flow cytometry. The predicted molecular weight is 92.7 kDa, and the supplier reports an observed band at about 120 kDa.
HIF-1α (HIF1A) is the oxygen-regulated subunit of hypoxia-inducible factor 1. In normal oxygen it is hydroxylated and rapidly degraded, but under hypoxia it accumulates, pairs with ARNT (HIF-1β) and switches on genes for erythropoietin, VEGF, glucose uptake and glycolysis. It is a central marker in studies of hypoxia, angiogenesis, tumor metabolism and ischemia.
| Target | Hypoxia-inducible factor 1-alpha (gene HIF1A; UniProt Q16665, human) |
|---|---|
| Clone | 17H18 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / IgG |
| Reactivity | Human |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 92.7 kDa |
| Observed MW | 120 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:30 |
| Flow cytometry | 1:30 |
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:1000, ECL detection.
Samples with confirmed staining (IHC): human kindey tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Samples with confirmed staining (ICC/IF): HeLa cells.
Immunogen
Synthetic peptide based on the sequence of human HIF-1 alpha.
Reactivity Notes
The supplier lists reactivity with human. UniProt places hypoxia-inducible factor 1-alpha in the cytoplasm, nucleus and nucleus speckle. Tissue expression noted by UniProt (human): Expressed in most tissues with highest levels in kidney and heart. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Chang Qu et al. (2024) Hypoxia Reversion and STING Pathway Activation through Large Mesoporous Nanozyme for Near-Infrared-II Light Amplified Tumor Polymetallic-Immunotherapy. ACS Nano. 10.1021/acsnano.4c05483
Xing Gao et al. (2025) Optimizing interventional therapy: A homogeneous lipiodol formulation of Tirapazamine and Sorafenib responsive to post-embolization microenvironment. Journal of Controlled Release. 10.1016/j.jconrel.2025.01.074
An Xiaohong et al. (2023) Inhibition of PDGFRβ alleviates endothelial cell apoptotic injury caused by DRP-1 overexpression and mitochondria fusion failure after mitophagy. Cell Death & Disease. 10.1038/s41419-023-06272-3
Yandai Lin et al. (2024) NIR-Mediated Pyroelectric Catalysis for Sustained ROS/RNS Generation and Advanced Cancer Therapy In Vivo via Injectable Hydrogel. ACS Applied Materials & Interfaces. 10.1021/acsami.4c05836
Wen Jiaxin et al. (2025) Short-Term DMOG treatment rejuvenates senescent mesenchymal stem cells by enhancing mitochondrial function and mitophagy through the HIF-1α/BNIP3 pathway. Stem Cell Research & Therapy. 10.1186/s13287-025-04422-2
Zhiqiang Feng et al. (2024) Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1a to inhibit autophagy. Phytomedicine. 10.1016/j.phymed.2024.155647
Weitong Zhang et al. (2022) Explore the mechanism and substance basis of Mahuang FuziXixin Decoction for the treatment of lung cancer based on network pharmacology and molecular docking. Computers in Biology and Medicine. 10.1016/j.compbiomed.2022.106293
Shan Kai et al. (2017) IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice. Cellular & Molecular Immunology. 10.1038/cmi.2017.12
Yongfeng Su et al. (2025) Hypoxia-Induced Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Regulate Macrophage Polarization and Enhance Angiogenesis to Promote Diabetic Wound Healing. Biomolecules. 10.3390/biom15111504
Yan Tang et al. (2021) Salidroside attenuates CoCl2-simulated hypoxia injury in PC12 cells partly by mitochondrial protection. European Journal of Pharmacology. 10.1016/j.ejphar.2021.174617
